NOVEMBER 2017CIOAPPLICATIONS.COM6NOV - 03 - 2017BIOTECHNOLOGY SPECIALCopyright © 2017 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Volume 02 - 20Published by ValleyMedia, Inc. To subscribe to CIO ApplicationsVisit www.cioapplications.com Graphics & ArtJohn ConnorDeclan ColeAnil Kumar VSalesTom Francistom@cioapplications.com510.330.5238Mailing Address:ValleyMedia, Inc.44790 S. Grimmer Blvd Suite 202, Fremont, CA 94538T:510.757.1040 EditorialBlurring the Lines between Science and Science Fiction Joe PhillipManaging Editoreditor@cioapplications.comJoe PhillipGrowing digitization and technological advancement has triggered bubbling of innovation in the biotech industry. This innovative branch of science is today has blurred the lines between science and science fiction. Biotechnology has wide application in the global market. And while other countries primarily use their biotechnology resources for pharmaceuticals and diagnostics, the United States of America has discovered many other usage points for this innovative branch of science.As a huge contributor of 30 percent to the American Biotechnology sector and the overall global market, Biotech has also created an increased demand in manpower and has opened up many opportunities for US citizens. In fact, market research states that there are a total of 2,349 public and private Biotechnology companies in the country, providing an average annual salary to its workers of up to USD 88,000, more than double the average US wage. This has triggered the growth of companies aiming to enhance their operational aspects not only in manufacturing aspect but in terms of finance, research and development, and safety. The agenda of do more with less is compelling biotech companies to assess their value from a selling, general and administrative prospect. Hence, there is wide scope within the Biotechnology sphere in the US, whether it's within the health, agriculture or industrial sectors, with obesity presenting a wide market of opportunities.On this note, we present to you "Top 25 Biotechnology Solution Providers ­ 2017". We hope the valuable though insights from innovative and leaders and the innovative solutions from leading companies featured in this edition will help you in your endeavours today, and tomorrow. Let us know your thoughts Managing EditorJoe PhillipAssistant Managing EditorLalrindiki Sailo Senior WritersClara MathewRoyce D'SouzaSoumik Ghosh Editorial StaffBen JacksonDaniel HolmesEzra BenjaminJames SmithNaomi DaleSpurthi Patil *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staff
< Page 5 | Page 7 >